BERLIN (AP) — German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.
Merck shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday.
The company is a separate entity from Merck & Co., which is based in the U.S.
Vox "Smart Take" Pushes Gun Confiscation. Here's What Would Happen If They Tried. - Bearing Arms - 2nd Amendment, Gun Confiscation
Nick Adams - Not a Single Illegal Immigrant in 7 Months... In Australia
Boom! Obama gets devastating reminder after blasting New Orleans' longtime 'structural inequality'
Ann Coulter - Small But Honest Columnist Again Forced to Correct Highest-Rated Show on Cable TV
Small But Honest Columnist Again Forced to Correct Highest-Rated Show on Cable TV | Human Events
Boehner reportedly tells Colorado donors: Ted Cruz is a “jackass” - Hot Air
Donald Trump Is Not a Racist. Don't Go Back to 2005, Republicans. | RedState